RAPT Therapeutics, Inc. — Director's Dealing 2021

Feb 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RAPT Therapeutics, Inc. (RAPT)
CIK: 0001673772
Period of Report: 2021-02-16

Reporting Person: Brockstedt Dirk G. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-16	Common Stock	M	8245	$6.3	Acquired	28057	Direct
2021-02-16	Common Stock	M	1632	$6.18	Acquired	29689	Direct
2021-02-16	Common Stock	S	9877	$21.22	Disposed	19812	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-16	Option (right to buy)	$6.18	M	1632	Disposed	2028-03-27	Common Stock (1632)	Direct
2021-02-16	Option (right to buy)	$6.30	M	8245	Disposed	2029-03-27	Common Stock (8245)	Direct

Footnotes

F1: Includes 2,256 shares acquired by the Reporting Person under the Issuer's 2019 Employee Stock Purchase Plan on May 1, 2020.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.